<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042597</url>
  </required_header>
  <id_info>
    <org_study_id>PKUPH-sarcoma 05</org_study_id>
    <nct_id>NCT04042597</nct_id>
  </id_info>
  <brief_title>Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma</brief_title>
  <acronym>CSSG-03</acronym>
  <official_title>A Prospective, Multicentre, Open-label, Randomised Phase 2 Trial to Study the Efficacy and Safety of Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Shougang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For local relapse not amenable to reasonable curative surgery or for those with metastatic
      chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular
      tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the
      platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a
      novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high
      affinity, which also showed broad antitumor activity against EGFR and so on. Thus this
      multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the
      efficacy and safety of anlotinib versus imatinib on advanced chordoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate, ORR</measure>
    <time_frame>6 months</time_frame>
    <description>CR+PR in the intent-to-treat population according to RECIST, version 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival, PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival is defined as time from randomisation to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment or randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, OS</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as time from randomisation to the first occurrence of death from any cause within 63 days of last response assessment or randomisation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Effect of Drugs</condition>
  <condition>Quality of Life</condition>
  <condition>Chordoma</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: anlotinib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anlotinib was given at a fixed dose of 12mg D1-14 every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: imatinib arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imatinib was given at dose of 400 mg twice daily continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>anlotinib was given at a fixed dose of 12mg D1-14 every 21 days</description>
    <arm_group_label>Arm A: anlotinib arm</arm_group_label>
    <arm_group_label>Arm B: imatinib arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older;

          -  histologically proven metastatic or locally advanced chordoma, reviewed by the
             Pathology Committee of Peking University People's Hospital;

          -  not amenable to curative-intent surgery;

          -  measurable with computed tomography scan or magnetic resonance imaging, per RECIST,
             version 1.1.

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG)30 performance status more than 2 ;

          -  life expectancy less than 12 weeks;

          -  with severe or uncontrolled medical disorders (â‰¥grade 2 of Common Terminology Criteria
             for Adverse Events version 4.03 [CTCAE version 4.03]) that could jeopardise the
             outcomes of the study, for example, cardiac clinical symptom or disease with LVEF
             (left ventricular ejection fraction) &lt;50%, hypertension that could not be well
             controlled through antihypertensive drugs and so on;

          -  weight loss of 20% or more before illness;

          -  brain or leptomeningeal metastasis;

          -  surgical procedure or radiotherapy within 4 weeks of enrollment;

          -  active gastroduodenal ulcer, previous condition associated with risk of bleeding or
             requiring anticoagulation;

          -  proteinuria or hematuria;

          -  denutrition with albuminemia less than 25 g/L;

          -  pregnant or breastfeeding status;

          -  other malignancy, positive HBV/HCV/HIV serology;

          -  known allergy to the experimental agents;

          -  had ever used anti-angiogenesis TKIs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Guo, M.D. and Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Musculoskeletal Tumor Center of Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Xie, M.D.</last_name>
    <phone>+8613401044719</phone>
    <email>xie.lu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Xu, M.D.</last_name>
    <phone>+8615901040835</phone>
    <email>xujie_pkuph@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tingting Ren, Ph. D.</last_name>
      <phone>+861380095026</phone>
      <email>tumorcenter@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chordoma</keyword>
  <keyword>unresectable</keyword>
  <keyword>anlotinib</keyword>
  <keyword>imatinib</keyword>
  <keyword>survival</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

